What's hot

View all perspectives
What's Hot
Sleep asleep

Sleep Quality & Psoriatic Arthritis

For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.

Read more →

Ultrasound in PsA

Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study

Watch video →

Tapering TNFi in nonradiographic AxSpA

Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.

Watch video →

Sunday (Day 2): ACR 22 Daily Recap

ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.

Watch video →

Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression

Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)

Watch video →

Deucravacitinib in PsA

Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial

Watch video →

Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial

Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)

Watch video →

Best of ACR Day Two in PSA

Watch video →

PET CT Imaging to Define Risk of Progression from PSO to PsA

Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.

Watch video →

ACR22 Daily Recap: Saturday Recap

Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate. 

Watch video →
      RT @uptoTate: 2000 IU/day vitamin D led to significantly reduced incidence of autoimmune diseases in Abs 1200 over 5.3 y

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      2000 IU/day vitamin D led to significantly reduced incidence of autoimmune diseases in Abs 1200 over 5.3 years, but after trial termination, protective effects dissipated and were no longer significant. #ACR22 @RheumNow https://t.co/sLwoxeCR3y https://t.co/47wpWXF1W7
      RT @AurelieRheumo: HCQ does not prevent RA in CCP+ pts w/out clinical arthritis!

      Stop RA: RCT HCQ vs. PBO in pts at-ris

      Aurelie Najm AurelieRheumo

      3 years 1 month ago
      HCQ does not prevent RA in CCP+ pts w/out clinical arthritis! Stop RA: RCT HCQ vs. PBO in pts at-risk Interim analysis 140+ pts RA development HCQ 34% vs. PBO 36% Trial interrupted as met futility criteria. https://t.co/n31OmsjLhM Abs#1604 #ACR22 @RheumNow #ACRBest https://t.co/NVYS8kB5to
      RT @ericdeinmd: 2022 ACR G/L for Integrative RA Intervent #ACR22
      1 strong rec: consistent exercisee
      27 conditional recs:

      Eric Dein ericdeinmd

      3 years 1 month ago
      2022 ACR G/L for Integrative RA Intervent #ACR22 1 strong rec: consistent exercisee 27 conditional recs: Rehab, Mediterr diet, against other diets, self-mgmt/CBT/acupunct Conditional against electrotherapy, chiropractor No rec for diet supplem BMI, 🚬: no RA spec recomm @RheumNow https://t.co/cVFr6beQuJ
      RT @RichardPAConway: Patel @draditipatel et al. Delay in starting ACE-I in Scleroderma Renal Crisis increased need for d

      Richard Conway RichardPAConway

      3 years 1 month ago
      Patel @draditipatel et al. Delay in starting ACE-I in Scleroderma Renal Crisis increased need for dialysis 75.6% vs 16.7%, p=0.023. No effect on overall survival. 5-year mortality 70%, 1 year mortality 58%. @RheumNow #ACR22 Abstr#1530 https://t.co/cdYhEtqcHT https://t.co/lDWJto1cF0
      RT @RichardPAConway: Mease et al. PsA - Early DMARD initiators (=<1 year following diagnosis) greater improvement in

      Richard Conway RichardPAConway

      3 years 1 month ago
      Mease et al. PsA - Early DMARD initiators (=<1 year following diagnosis) greater improvement in outcomes than late initiators (at least in MDA) in CorEvitas. @RheumNow #ACR22 Abstr#1493 https://t.co/oadxbG8TKS https://t.co/245xVTcKx1
      RT @RichardPAConway: Nabi. Biosimilar to biosimilar IFX switch in DANBIO. High retention rate - 92% in originator-experi

      Richard Conway RichardPAConway

      3 years 1 month ago
      Nabi. Biosimilar to biosimilar IFX switch in DANBIO. High retention rate - 92% in originator-experienced equiv to normal drop off at 1 year on a biologic. Lower retention 83% in originator-naive switchers = likely nocebo effect @RheumNow #ACR22 Abstr#1112 https://t.co/oa1SawWWs4 https://t.co/iU3doB9jV4
      RT @doctorRBC: New biomarkers of increased disease activity in PsA?
      Tissue remodeling and inflammation (neutrophil activ

      Robert B Chao, MD doctorRBC

      3 years 1 month ago
      New biomarkers of increased disease activity in PsA? Tissue remodeling and inflammation (neutrophil activity and fibrosis) biomarkers showed best performance in differentiating PsA w/ flares and without. Abs#1610 @RheumNow #ACR22 https://t.co/73ta7VXgTY
      RT @RichardPAConway: Kiltz et al. Greater efficacy of secukinumab in normal BMI than high BMI AS patients. Decremental e

      Richard Conway RichardPAConway

      3 years 1 month ago
      Kiltz et al. Greater efficacy of secukinumab in normal BMI than high BMI AS patients. Decremental effect with increasing BMI. @RheumNow #ACR22 Abstr#1495 https://t.co/zwEmQsJmPT https://t.co/nOW2IbTc5t
      RT @RichardPAConway: Dörner et al. Remibrutinib (BTKi) in pSS. + study in pSS! Improved ESSDAI (disease activity), no e

      Richard Conway RichardPAConway

      3 years 1 month ago
      Dörner et al. Remibrutinib (BTKi) in pSS. + study in pSS! Improved ESSDAI (disease activity), no effect ESSPRI (PRO), trend to improve salivary flow, + effect on multiple labs. @RheumNow #ACR22 Abstr#1113 https://t.co/m2rvXbqq7b https://t.co/jQLyP66zX9
      RT @RichardPAConway: Benesova et al. Higher treatment response to secukinumab in both male and female AS patients when d

      Richard Conway RichardPAConway

      3 years 1 month ago
      Benesova et al. Higher treatment response to secukinumab in both male and female AS patients when diagnosed earlier. No such effect seen in PsA patients. Emphasises need to reduce diagnostic delay in AS. @RheumNow #ACR22 Abstr#1497 https://t.co/9g2zN85a33 https://t.co/LfvQFTKr69
      RT @AurelieRheumo: Promising results for Izokibep in PsA

      Ph2 RCT meets primary endpoint at Wk 16

      ACR50: 13% PBO 48%

      Aurelie Najm AurelieRheumo

      3 years 1 month ago
      Promising results for Izokibep in PsA Ph2 RCT meets primary endpoint at Wk 16 ACR50: 13% PBO 48% 40mg IZO 52% 80mg IZO MDA: 5% PBO 42% 40mg 39% 80mg Results observed as soon as wk2 No new safety signal compared to IL17Ai https://t.co/Gilhg5k36b Abs#1597 #ACR22 @RheumNow https://t.co/VvxSRLtkFk
      RT @bella_mehta: Protective effect of #allopurinol in gout
      Dose dependent reduction in risk of acute coronary syndrome

      Bella Mehta bella_mehta

      3 years 1 month ago
      Protective effect of #allopurinol in gout Dose dependent reduction in risk of acute coronary syndrome in incident #Gout #ACR22 @RheumNow abst#1582 https://t.co/PrEtRwvLvm
      RT @uptoTate: Abs 1187 apremilast may have beneficial effects on cardiometabolic measures including reductions in HbA1c

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      Abs 1187 apremilast may have beneficial effects on cardiometabolic measures including reductions in HbA1c in severely obese patients and reductions in weight and dz activity improvements in PsO/ PsA outcomes across all BMI categories. #ACR22 @RheumNow https://t.co/fCdJxz2IDk https://t.co/mLnwKQs539
      RT @uptoTate: Enjoy the post-session adult beverage #ACR22 and #rheumtwitter but, choose wisely as Abs 1206 finds beer c

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      Enjoy the post-session adult beverage #ACR22 and #rheumtwitter but, choose wisely as Abs 1206 finds beer consumption was consistently assoc'd w/ higher serum urate levels, whereas sake showed only modest associations in both males and females. @RheumNow https://t.co/ETtU31iTZ0 https://t.co/keG5IN7LbC
      Catch our daily recap LIVE at 5pm ET. #ACR22 https://t.co/OpPcGhnWJ1

      Dr. John Cush RheumNow

      3 years 1 month ago
      Catch our daily recap LIVE at 5pm ET. #ACR22 https://t.co/OpPcGhnWJ1

      Podcasts

      • ACR2022 - Day 4 00:14:40
      • Monday ACR 2022 Daily Recap 00:37:20
      • ACR2022 - Day 3.3 00:34:23

      Catch up on Conference Podcasts

      ×